Jasper Therapeutics
JSPR
58 hedge funds and large institutions have $13.9M invested in Jasper Therapeutics in 2026 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 9 closing their positions.
340% more call options, than puts
Call options by funds: $110K | Put options by funds: $25K
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
15% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 13
5% more funds holding
Funds holding: 55 → 58 (+3)
12.18% less ownership
Funds ownership: 68.69% → 56.51% (-12%)
61% less capital invested
Capital invested by funds: $35.2M → $13.9M (-$21.3M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
+$1.88M |
| 2 |
Millennium Management
New York
|
+$755K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$371K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$147K |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$106K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$3.2M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$1.9M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$1.77M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$888K |
| 5 |
Morgan Stanley
New York
|
-$883K |
JSPR Hedge Fund Activity: Q1 2026 in Review
58 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q1 2026, worth a combined $13.9M — down 61% from $35.2M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new JSPR positions and 9 closed out — a net gain of 4 holders — while 15 added to existing stakes and 13 trimmed.
The largest buyer was Kingdon Capital Management, opening a new position worth an estimated $1.88M. The largest seller was Goldman Sachs, exiting entirely with an estimated $3.2M sold.
- 58 institutional investors held Jasper Therapeutics (JSPR) as of Q1 2026, up from 55 in Q4 2025.
- Funds reported $13.9M of Jasper Therapeutics stock for Q1 2026, down 61% quarter-over-quarter.
- 13 funds opened new Jasper Therapeutics positions in Q1 2026 and 9 closed out, a net change of +4 holders.
- The largest Jasper Therapeutics buyer in Q1 2026 was Kingdon Capital Management, an estimated $1.88M added.
- The largest Jasper Therapeutics seller in Q1 2026 was Goldman Sachs, an estimated $3.2M sold.
Based on aggregated 13F filings for Q1 2026.